https://www.selleckchem.com/pr....oducts/skf-34288-hyd
Most studies included majority female (n = 19, 68%) and non-White populations (n = 15, 54%), while fewer reported socioeconomic (n = 11, 39%) or insurance status (n = 9, 32.1%). Most studies assessed implementation outcomes of feasibility (n = 27, 96%) and acceptability (n = 19, 68%); costs (n = 3, 11%), penetration (n = 1, 4%), and sustainability (n = 1, 4%) were infrequently assessed. PRO implementation in routine clinical care for diverse and underrepresented patient populations is generally feasible and acceptable. R
Like
Comment
Share
